Results 41 to 50 of about 59,179 (315)

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

open access: yesHepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole   +12 more
wiley   +1 more source

Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy. [PDF]

open access: yes, 2013
BACKGROUND/AIM: In randomised controlled trials (RCTs) of ursodeoxycholic acid (UDCA), although serum bilirubin is frequently reduced, its effect on disease progression and mortality is unclear.
Burroughs, Andrew K   +5 more
core   +1 more source

Association of Primary Biliary Cirrhosis with Opsoclonus Myoclonus Syndrome

open access: yesAsian Journal of Medical Sciences, 2011
Primary biliary cirrhosis is an autoimmune disorder affecting exclusively liver. There has been association of this autoimmune disease with various other neurological counterparts, but Opsoclonus-Myoclonus Syndrome in conjunction with primary biliary ...
Anil T Kumar
doaj   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

open access: yesHepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr   +19 more
wiley   +1 more source

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection [PDF]

open access: yes, 2008
Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrhosis, often have severe consequences for the patient. Because of a lack of appropriate animal models, not much is known about their potential viral etiology. Infection
Hintereder, Gudrun   +23 more
core   +1 more source

Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study

open access: yesBMC Gastroenterology, 2012
Background Up to now, few data are available regarding the clinical characteristics of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome.
Zhao Pan, Han Yukun
doaj   +1 more source

Explainable AI for Enhanced Interpretation of Liver Cirrhosis Biomarkers

open access: yesIEEE Access, 2023
Liver cirrhosis is a terminal pathological result of chronic liver damage, illicit drugs, hepatotoxicity, and non-alcoholic steatohepatitis. Assessment of liver cirrhosis via non-invasive methods in order to circumvent the limitations of liver biopsy ...
Greeshma Arya   +5 more
doaj   +1 more source

Primary Biliary Cirrhosis in the Era of Liver Transplantation

open access: yesAnnals of Transplantation, 2014
Primary biliary cirrhosis (PBC) is an autoimmune disease of the liver, characterized by the presence of antimitochondrial antibodies (AMA) and progressive immune-mediated destruction of biliary ductules, which lead to cirrhosis. Theories of the PBC etiopathogenesis assume that the disease develops secondarily as an improper immunological reaction to ...
Joanna Raczyńska   +5 more
openaire   +2 more sources

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. [PDF]

open access: yes, 2013
Cystic Fibrosis associated liver disease (CFLD) develops in approximately 30% of CF patients. However, routine sensitive diagnostic tools for CFLD are lacking. Within this study, we aimed to identify new experimental biomarkers for the detection of CFLD.
Richard Schulz   +26 more
core   +1 more source

Home - About - Disclaimer - Privacy